Astrazeneca posted a strong rise in first-half revenue and improvement in profit and cashflows as Britain’s biggest drugs company continued to benefit from the launch of new blockbuster drugs.
The Cambridge-based pharmaceutical company posted a 14 per cent rise in revenue at constant currencies to $12.6 billion in the six months to the end of June, boosted by growth across its three therapy areas and across all its regions.
Sales of new medicines rose by 45 per cent to $6.4 billion and now represent half of Astrazeneca’s total global revenue.
Oncology sales, which has become a therapeutic focus for Astrazeneca, rose by 31 per cent to $5.3 billion, once more led by its trio of new cancer treatments, Tagrisso, Imfinzi and Lynparza.
Revenue in
